Silk Road Medical, Inc (SILK)
Chart Events
Performance Outlook
| Previous Close | 53.14 |
| Open | 53.00 |
| Bid | 52.11 x 800 |
| Ask | 52.25 x 900 |
| Day's Range | 52.10 - 54.01 |
| 52 Week Range | 20.84 - 75.80 |
| Volume | 95,901 |
| Avg. Volume | 326,114 |
| Market Cap | 1.778B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.21 |
| Earnings Date | Mar 01, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 67.83 |
Fair Value
Related Research
- GlobeNewswire
Silk Road Medical to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
SUNNYVALE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 1, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3554549. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/. About Silk Road MedicalSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook. Investor Contact:Lynn Lewis or Caroline PaulGilmartin Groupinvestors@silkroadmed.com
- Newsfile
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silk Road Medical, Inc. - SILK
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silk Road Medical, Inc. ("Silk Road" or the "Company") (NASDAQ: SILK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Silk Road and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here ...
- Insider Monkey
Is Silk Road Medical (SILK) Stock a Buy For 2021?
Baron Discovery Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here. During the fourth quarter of 2020, the Baron Discovery Fund returned 25.54% (institutional shares). This was 4.07% lower than the Russell 2000 Growth Index, the Fund’s primary benchmark index. You should check out Baron Discovery Fund’s top 5 […]
